| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 83,159 | 92,437 | ||
| Marketable securities | 412,513 | 460,641 | ||
| Total cash, cash equivalents, and marketable securities | 495,672 | 553,078 | ||
| Accounts and accrued receivable | 41,456 | 47,310 | ||
| Restricted cash | 25,000 | 25,000 | ||
| Other current assets | 133,012 | 116,757 | ||
| Total current assets | 695,140 | 742,145 | ||
| Property and equipment, net | 427,358 | 424,020 | ||
| Gross carrying amount | 91,133 | - | ||
| Accumulated amortization | 51,812 | - | ||
| Intangible assets, net | 39,321 | 40,262 | ||
| Goodwill | 47,806 | 47,806 | ||
| Investments in equity accounted investees | 93,301 | 90,374 | ||
| Other long-term assets | 53,066 | 57,454 | ||
| Total long-term assets | 660,852 | 659,916 | ||
| Total assets | 1,355,992 | 1,402,061 | ||
| Accounts payable and other current liabilities | 53,117 | 50,074 | ||
| Contingent consideration payable | 0 | 0 | ||
| Deferred revenue | 15,687 | 16,949 | ||
| Total current liabilities | 68,804 | 67,023 | ||
| Operating lease liability | 137,052 | 137,184 | ||
| Deferred revenue | 5,850 | 11,633 | ||
| Deferred government contributions | 169,118 | 167,532 | ||
| Deferred tax liability | 9,744 | 10,053 | ||
| Other long-term liabilities | 1,386 | 1,560 | ||
| Total long-term liabilities | 323,150 | 327,962 | ||
| Total liabilities | 391,954 | 394,985 | ||
| Common shares no par value, unlimited authorized shares at december31, 2024 and september30, 2025 295,757,002 and 299,011,566 shares issued and outstanding at december31, 2024 and september30, 2025, respectively | 794,469 | 791,668 | ||
| Additional paid-in capital | 192,804 | 181,483 | ||
| Accumulated other comprehensive loss | -2,698 | -2,657 | ||
| Accumulated earnings (deficit) | -20,537 | 36,582 | ||
| Total shareholders' equity | 964,038 | 1,007,076 | ||
| Total liabilities and shareholders' equity | 1,355,992 | 1,402,061 | ||
AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL)